ArticleAPL bioengineering2025
Metronomic photodynamic therapy for deep organ cancer by implantable wireless OLEDs.
Article in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Soft, Flexible, and Stretchable Platforms for Tissue-Interfaced Bioelectronics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Next-generation dynamic and combinatorial nanotherapies for liver cancer: mechanisms, current advances and future perspectives.Journal of nanobiotechnology · 2026Review
- Implanted Miniature Light Devices for Phototherapeutics.Advanced therapeutics · 2026Article
- Polymeric Nanoparticle-Mediated Photodynamic Therapy: A Synergistic Approach for Glioblastoma Treatment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- 5-Aminolevulinic Acid-Mediated Metronomic Photodynamic Therapy for Mouse Mammary Tumors.Yonago acta medica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metronomic photodynamic therapy (mPDT) is a method of continuously delivering low-intensity light to a cancer lesion. This approach does not require high-intensity light, enabling the miniaturization of light devices and making them suitable for implantation within the body. However, the application of mPDT to tumors in deep organs such as the liver and pancreas has yet to reach practical implementation. In this study, we developed an mPDT system designed to meet three key requirements deemed essential for practical use: (1) uniform light irradiation throughout the tumor, (2) maintenance of constant light intensity within the body with sufficient operational duration, and (3) avoidance of immunological complications and thermal damage. The newly constructed mPDT system incorporates an ultra-thin organic light-emitting diode (OLED) device and wireless energy transfer technology, allowing it to be designed for implantation in deep organs. In experiments using a rat model of orthotopic hepatoma, the new mPDT system effectively induced widespread cell death deep within the tumor and exhibited high therapeutic efficacy against cancer. This study is the first study to demonstrate that mPDT utilizing a biocompatible and wirelessly powered OLED device has strong anti-tumor effects against parenchymal organ cancers. The findings represent a significant advancement toward the clinical application of mPDT for the treatment of deep organ cancers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.